Loading organizations...
§ Private Profile · Dublin, Ireland
AI-driven digital pathology platforms & services for healthcare and life sciences, improving diagnostic accuracy and efficiency.
Founded in 2017 and led by Chief Executive Officer Donal O'Shea alongside Chief Operating Officer Mairin Rafferty, Dublin-based Deciphex develops AI-driven digital pathology platforms and services designed to improve diagnostic accuracy and streamline research workflows. The company provides software solutions such as Diagnexia and Patholytix, which connect healthcare providers with global subspecialty pathologist networks and facilitate complex drug safety evaluations and research. Deciphex serves life sciences organizations and major healthcare systems, including various NHS Trusts, and recently migrated its artificial intelligence training operations to Oracle Cloud Infrastructure. The enterprise has raised a total of $67,360,000 in venture capital funding to date, which includes a recent $32,300,000 financing round and an earlier $11,500,000 Series B led by ACT Venture Capital. These investments support the expansion of its clinical diagnostics and pharmaceutical applications to address global clinician shortages.
Deciphex has raised $76.9M across 7 funding rounds.
Deciphex has raised $76.9M in total across 7 funding rounds.
Deciphex has raised $76.9M across 7 funding rounds. Most recently, it raised $17.6M Debt in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 2, 2025 | $17.6M Debt Financing | Joey Mason | — | Announced |
| Jan 1, 2025 | $32M Series C | — | ACT Venture Capital, Amino Collective, Hummingbird Ventures, MizMaa Ventures, Molten Ventures, NOT Boring Capital, Seroba Life Sciences, Charles River Laboratories, HBAN Medtech Syndicate, Irrus Investments, Nextsteps Capital | Announced |
| Jan 1, 2023 | $4M Series B | Seroba Life Sciences | ACT Venture Capital, Molten Ventures | Announced |
| May 1, 2022 | $12M Series B | ACT Venture Capital | Molten Ventures, Seroba Life Sciences, Charles River Laboratories, HBAN Medtech Syndicate, Irrus Investments, Nextsteps Capital, Novartis | Announced |
| Jul 1, 2020 | $6M Series A | — | ACT Venture Capital, Molten Ventures, Seroba Life Sciences | Announced |
| May 21, 2019 | $2.3M Venture Round | — | ACT Venture Capital, Enterprise Ireland, GI Partners OF Illinois, Inova Personalized Health Accelerator, Irrus Investments, Nextsteps Capital | Announced |
| Apr 1, 2019 | $3M Series U | — | ACT Venture Capital, Molten Ventures, Seroba Life Sciences | Announced |
Deciphex is a Dublin-based technology company specializing in AI-powered digital pathology platforms that enhance diagnostic efficiency for healthcare providers and pharmaceutical firms. Founded in 2017, it offers three core brands—Diagnexia, Patholytix, and Diagnexia Analytix—that connect global networks of subspecialty pathologists with AI-driven workflows, digital imaging, and analytics to accelerate diagnoses, streamline drug development, and improve patient outcomes.[1][2][3] These solutions serve hospitals (e.g., reducing NHS wait times from 2 months to 2 days), top pharma companies (speeding preclinical testing), and life sciences organizations facing pathology shortages, with recent €31M ($32.3M) Series C funding in January 2025 fueling global expansion.[3][4]
Deciphex was founded in 2017 in Dublin, Ireland, by CEO Donal O'Shea, a serial entrepreneur with a Ph.D. in Computer Vision from Dublin City University and over 20 years in life sciences, diagnostics, and technology, including prior startup exits via trade sales.[1][2] The idea emerged from recognizing the pathology productivity gap—limited resources, long wait times, and inefficient workflows—and transitioned traditional methods to AI by optimizing image capture, global pathologist networks, and AI analysis for clinical trials and diagnostics.[2][3] Early traction built through platforms like Diagnexia for rapid diagnostics and Patholytix for GLP-compliant research, culminating in partnerships with 9/10 top pharma companies and NHS integration; pivotal growth included the 2025 Series C round led by Molten Ventures and key hires like CFO Greg Wigmore.[3][4]
Deciphex stands out in digital pathology through integrated AI and human expertise:
Deciphex rides the AI-digital pathology wave, addressing global shortages amid rising cancer rates and diagnostic demands, where traditional microscopy lags.[1][3] Timing aligns with healthcare digitization post-COVID, regulatory shifts favoring AI (e.g., GLP compliance), and pharma's push for faster trials amid $2T+ annual R&D spends.[2][3] Market forces like NHS 28-day diagnosis targets and underserved regions amplify its impact, democratizing expertise while competitors like Paige and Ibex focus narrower on cancer AI.[1] It influences the ecosystem by pioneering data repositories for foundation models, enabling broader AI adoption in pathology and bridging clinical-research gaps for improved drug safety and equity.[3]
Deciphex is primed for hypergrowth, leveraging its €31M raise to expand AI models, global networks, and pharma partnerships amid a pathology crisis projected to worsen.[4] Trends like multimodal AI, real-world evidence mandates, and telepathology will shape its path, potentially capturing share from fragmented markets. Its influence may evolve into an industry standard-setter, powering next-gen diagnostics and trials—transforming "productivity gap" into abundance, much like how it already cut NHS waits from months to days.[3]
Deciphex has raised $76.9M in total across 7 funding rounds.
Deciphex's investors include Joey Mason, Act Venture Capital, Amino Collective, Hummingbird Ventures, MizMaa Ventures, Molten Ventures, Not Boring Capital, Seroba Life Sciences, Charles River Laboratories, HBAN Medtech Syndicate, Irrus Investments, Nextsteps Capital.